Insight Molecular Diagnostics Inc.

IMDXNASDAQHealthcare● Active

$5.98

+$0.26(+4.60%)

Market Cap$160592473

P/E Ratio—

52W High$8.51

52W Low$2.33

Avg Volume350K

Open$5.75

Beta1.79

Cash on Hand Financials Revenue

Insight Molecular Diagnostics Inc. (IMDX) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

IMDX · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$11.6M▲ +34.1% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$11.6M

cashAndCashEquivalents

Short-Term Investments

shortTermInvestments

YoY Change vs Prior Year

+34.1%

vs prior fiscal year

Latest Quarter

$28.2M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$11.6MCash on Hand

Total Debt$3.5MTotal Debt

Net Cash / Net Debt+$8.1MNet Cash Position

Cash vs Debt Ratio

Cash 77%Insight Molecular Diagnostics Inc. cash as % of market cap: 7.21%% · MCap $0BDebt 23%

Insight Molecular Diagnostics Inc. has a net cash position of $8.1M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$11.6M − $3.5M = +$8.1M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

IMDX annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

IMDX cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$11.6M+34.1%

Dec 31, 2024FY$8.6M-8.4%

Dec 31, 2023FY$9.4M-53.8%

Dec 31, 2022FY$20.4M-39.7%

Dec 31, 2021FY$33.9M+333.0%

IMDX cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

IMDX vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Insight Molecular Diagnostics Inc.YOU

IMDX

$11.6M$154M7.5%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Insight Molecular Diagnostics Inc. (IMDX) cash on hand as of December 31, 2025 is $11.6M, comprising $11.6M in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Insight Molecular Diagnostics Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Insight Molecular Diagnostics Inc. cash reserves or cash position.

Insight Molecular Diagnostics Inc. annual cash on hand history shows increased +34.1% in 2025: increased +34.1% in 2025. Insight Molecular Diagnostics Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Insight Molecular Diagnostics Inc. carries total debt of $3.5M against cash of $11.6M, resulting in a net cash position of +$8.1M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

IMDX cash on hand · 5 questions

As of December 31, 2025, Insight Molecular Diagnostics Inc. (IMDX) has $11,583,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $11,583,000 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $28,201,000. Data sourced from the annual 10-K filing via FMP.

IMDX cash on handIMDX cash reservesIMDX cash 2025how much cash does IMDX have

▸ Source: FMP /balance-sheet-statement · US GAAP · Insight Molecular Diagnostics Inc. · Insight Molecular Diagnostics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025